ArticleFrontiers in oncology2026
Arnica/Levisticum 6x comp. can alleviate musculoskeletal symptoms in breast cancer patients undergoing endocrine therapy: a case series.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignancy among women worldwide, and endocrine therapy (ET) is crucial for reducing recurrence and mortality in hormone receptor-positive cases. However, ET is often associated with adverse effects, especially musculoskeletal symptoms (MSS) such as arthralgia and myalgia, which impair daily functioning, decrease quality of life, and lead to early therapy discontinuation. Although some pharmacological and non-pharmacological options are available for managing ET-induced MSS, their effectiveness is limited, and so far, no general recommendations exist. In the context of integrative oncology, which combines conventional and complementary approaches, anthroposophic medicine has been proposed as a supportive strategy to address these challenges. This case series investigated the potential of the anthroposophic medicinal product
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.